- Home
- LPSN vs CLYM Comparison
LPSN vs CLYM Comparison
Compare LPSN & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPSN
- CLYM
- Stock Information
- Founded
- LPSN 1995
- CLYM 2018
- Country
- LPSN United States
- CLYM United States
- Employees
- LPSN N/A
- CLYM N/A
- Industry
- LPSN EDP Services
- CLYM
- Sector
- LPSN Technology
- CLYM
- Exchange
- LPSN Nasdaq
- CLYM NYSE
- Market Cap
- LPSN 72.8M
- CLYM 86.5M
- IPO Year
- LPSN 2000
- CLYM 2021
- Fundamental
- Price
- LPSN $0.74
- CLYM $1.22
- Analyst Decision
- LPSN Hold
- CLYM Buy
- Analyst Count
- LPSN 3
- CLYM 1
- Target Price
- LPSN $1.20
- CLYM $10.00
- AVG Volume (30 Days)
- LPSN 833.9K
- CLYM 204.9K
- Earning Date
- LPSN 07-30-2025
- CLYM 08-13-2025
- Dividend Yield
- LPSN N/A
- CLYM N/A
- EPS Growth
- LPSN N/A
- CLYM N/A
- EPS
- LPSN N/A
- CLYM N/A
- Revenue
- LPSN $292,025,000.00
- CLYM N/A
- Revenue This Year
- LPSN N/A
- CLYM N/A
- Revenue Next Year
- LPSN $0.82
- CLYM N/A
- P/E Ratio
- LPSN N/A
- CLYM N/A
- Revenue Growth
- LPSN N/A
- CLYM N/A
- 52 Week Low
- LPSN $0.53
- CLYM $1.05
- 52 Week High
- LPSN $2.08
- CLYM $9.21
- Technical
- Relative Strength Index (RSI)
- LPSN 45.79
- CLYM N/A
- Support Level
- LPSN $0.68
- CLYM N/A
- Resistance Level
- LPSN $0.79
- CLYM N/A
- Average True Range (ATR)
- LPSN 0.05
- CLYM 0.00
- MACD
- LPSN 0.00
- CLYM 0.00
- Stochastic Oscillator
- LPSN 40.29
- CLYM 0.00
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.